Are you interested in learning about new, emerging therapies that could potentially restore hearing? Would you like to stay apprised of new clinical trials for individuals with sensorineural hearing loss (SNHL) – and learn how to enroll?
In this program, Frequency Therapeutics’ Chief Development Officer, Dr. Carl LeBel, provided an overview of outcomes from four completed clinical trials of FX-322, the Company’s product candidate, which is the first to have shown meaningful hearing improvements in clinical studies. Individuals that showed these improvements included those with a range of hearing loss severities and causes, and Dr. LeBel discussed the types of hearing loss where Frequency is currently focused. Grace Fitzgerald, Director of Clinical Operations for Frequency, shared information about a current clinical trial for FX-322 with sites across the country and opportunities for individuals to enroll. A Q&A discussion followed the presentation.
Frequency’s hearing program focuses on addressing the underlying cause of SNHL by regenerating cells in the ear that are necessary for healthy hearing.
Note: HLAA does not endorse products or services featured and the presentation is paid for by the presenting company.
Chief Development Officer, Frequency Therapeutics
Carl LeBel, Ph.D., has been the Chief Development Officer at Frequency Therapeutics since 2018. He started LeBel Consulting LLC after serving as the Chief Scientific Officer at Otonomy, Inc., from 2009 to 2016. Before joining Otonomy, he was President and CEO of Akesis Pharmaceuticals, Inc., a virtual metabolic disorders company, and... Read More >
Director of Clinical Operations, Frequency Therapeutics
Grace Fitzgerald has been the Director of Clinical Operations at Frequency Therapeutics since 2020. Prior to joining Frequency, Grace was at ICON overseeing large global phase III studies and at Otonomy, Inc. conducting trials that involve intratympanic delivery for Meniere’s Disease. She also had trial oversight responsibilities for pediatric trials in... Read More >